D. Schlichting
Impact in
- Rheumatology top 5%
- Rheumatoid Arthritis Research and Therapies
- Systemic Lupus Erythematosus Research
- Dermatology top 5%
- Dermatology and Skin Diseases
Papers in
- Rheumatology 24
- Rheumatoid Arthritis Research and Therapies 23
- Systemic Lupus Erythematosus Research 8
- Genetics 8
- Chronic Lymphocytic Leukemia Research 8
- Inflammatory Bowel Disease 2
- Co-authors
- C. Gaich (8 shared papers)William L. Macias (6 shared papers)Alan Menter (1 shared paper)Jonathan Janes (1 shared paper)X. Zhang (1 shared paper)Kim Papp (1 shared paper)Maitreyi Raman (1 shared paper)Damon Disch (1 shared paper)
- Journals
- Annals of the Rheumatic Diseases (14 papers)The Journal of Rheumatology (2 papers)European Journal of Radiology (1 paper)Lara D. Veeken (1 paper)British Journal of Dermatology (1 paper)
- Partner nations
- United StatesUnited KingdomCanada
In The Last Decade
D. Schlichting
27 papers receiving 361 citations
Peers
Comparison fields: 5 of 43
- Rheumatology 205
- Dermatology 89
- Hematology 92
- Immunology 158
- Genetics 65
Countries citing papers authored by D. Schlichting
This map shows the geographic impact of D. Schlichting's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Schlichting with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Schlichting more than expected).
Fields of papers citing papers by D. Schlichting
This network shows the impact of papers produced by D. Schlichting. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Schlichting. The network helps show where D. Schlichting may publish in the future.
Co-authors
The 25 scholars most cited alongside D. Schlichting, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 27 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2016 | 208 | |
| 2 | 2015 | 24 | |
| 3 | 2015 | 20 | |
| 4 | 2021 | 18 | |
| 5 | Baricitinib Versus Placebo or Adalimumab in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to Background Methotrexate Therapy: Results of a Phase 3 Study | 2015 | 15 |
| 6 | 2012 | 14 | |
| 7 | 24-Week Results of a Blinded Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Januse Kinase 2 Inhibitor, in Combination with Traditional Disease Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis. | 2012 | 10 |
| 8 | 2020 | 9 | |
| 9 | Magnetic Resonance Imaging Substudy in a Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis. | 2012 | 8 |
| 10 | 2019 | 7 | |
| 11 | 12-and 24-Week Patient-Reported Outcomes From a Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis | 2012 | 5 |
| 12 | 2016 | 5 | |
| 13 | 2015 | 5 | |
| 14 | 2017 | 3 | |
| 15 | 2016 | 3 | |
| 16 | 2016 | 3 | |
| 17 | Microarray Pathway Analysis Comparing Baricitinib and Adalimumab in Moderate to Severe Rheumatoid Arthritis Patients, from a Phase 3 Study | 2017 | 2 |
| 18 | Baricitinib, an Oral Janus Kinase (JAK) 1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to cDMARD Therapy: Results of the Phase 3 RA-BUILD Study | 2016 | 2 |
| 19 | 2013 | 2 | |
| 20 | Rapid and Sustained Pain Improvement in Rheumatoid Arthritis Patients Treated with Baricitinib Compared to Adalimumab or Placebo | 2017 | 1 |
About D. Schlichting
D. Schlichting is a scholar working on Rheumatology, Genetics, Oncology, Neurology and Hematology, having authored 27 papers that have together received 371 indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (23 papers), Cytokine Signaling Pathways and Interactions (8 papers), Chronic Lymphocytic Leukemia Research (8 papers), Systemic Lupus Erythematosus Research (8 papers), Peripheral Neuropathies and Disorders (4 papers), Autoimmune and Inflammatory Disorders Research (4 papers), Inflammatory Bowel Disease (2 papers) and Pharmacological Effects of Natural Compounds (2 papers). The work is most often cited by research in Rheumatology (205 citations), Dermatology (89 citations), Hematology (92 citations), Immunology (158 citations) and Genetics (65 citations). D. Schlichting has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include C. Gaich, William L. Macias, Alan Menter, Jonathan Janes, X. Zhang, Kim Papp, Maitreyi Raman, Damon Disch, Scott D. Beattie and M. C. Genovese. Their work appears in journals such as Annals of the Rheumatic Diseases, The Journal of Rheumatology, European Journal of Radiology, Lara D. Veeken and British Journal of Dermatology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.